Silvia Sommerfeldt

Vienna General Hospital — Austria

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index119citations7works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(6), Hepatocellular Carcinoma Treatment and Prognosis(2), Venous Thromboembolism Diagnosis and Management(2), Colorectal Cancer Treatments and Studies(2), Inflammatory Biomarkers in Disease Prognosis(2)

Publications7 total

Activity of neoadjuvant bevacizumab at the time of surgery after 6 weeks of preoperative cessation: A translational study.
Journal of Clinical Oncology·2012
Activity of bevacizumab at the time of surgery after 6 weeks of preoperative cessation.
Journal of Clinical Oncology·2012· 1 cited
Discrimination between Circulating Endothelial Cells and Blood Cell Populations with Overlapping Phenotype Reveals Distinct Regulation and Predictive Potential in Cancer Therapy
Neoplasia·2011· 19 citedOpen Access
The role of myelosuppression in synergy between chemotherapy and anti-VEGF treatment.
Journal of Clinical Oncology·2011
Myelosuppression of Thrombocytes and Monocytes Is Associated with a Lack of Synergy between Chemotherapy and Anti-VEGF Treatment
Neoplasia·2011· 17 citedOpen Access
Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts.
PubMed·2011· 40 citedOpen Access
Platelet-Stored Angiogenesis Factors: Clinical Monitoring Is Prone to Artifacts
Disease Markers·2011· 42 citedOpen Access

Frequent Co-authors

Patrick Starlinger(7), Dominic Schauer(7), Christine Brostjan(7), P. C. Brugger(5), Irene Kuehrer(5), Sebastian F. Schoppmann(5), Michael Gnant(5), Dietmar Tamandl(5), Lejla Alidzanovic(4), Thomas Maier(2), Birgit Gruenberger(2), Thomas Gruenberger(2), Christian Reiter(1), Beata Herberger(1), Beata Perisanidis(1)